Therapeutic Lipidology Table of ContentsnnChapter 1nLipoprotein Metabolism and Vascular BiologynBrian G. Choi, M.D., M.B.A.nJuan J. Badimon, Ph.D.nPedro R. Moreno, M.D.nValentin Fuster, M.D., Ph.D.nLipoprotein ClassificationnApolipoprotein ClassificationnLipid MetabolismnHDL MetabolismnLipoprotein Metabolism RegulationnLipids in Vascular Biology and AtherothrombosisnnChapter 2nGenetic Disorders of Lipoprotein MetabolismnMarina Cuchel, M.D., Ph.D.nAtif Qasim, M.D.nDaniel J. Rader, M.D.nLipid Disorders Involving Elevated TriglyceridesnInherited Syndromes of Elevated LDL-CholesterolnInherited Syndromes of Low LDL-CholesterolnInherited Syndromes of Low HDL-CnInherited Syndromes of Elevated HDL-C LevelsnnChapter 3nInternational Guidelines for Dyslipidemia ManagementnCathleen E. Maki, R.N., M.S.N., N.P.nThe Canadian GuidelinesnThe European GuidelinesnJoint British Societies GuidelinesnnChapter 4nPathophysiology and Management of Dyslipidemias Associated withnObesity, Type 2 Diabetes and Other Insulin Resistant StatesnKevin C. Maki, Ph.D.nObesity and Type 2 Diabetes MellitusnCardiometabolic Risk SyndromenLipid Abnormalities Associated with Insulin ResistancenFunctions of InsulinnExcessive Production of Very-low Density Lipoproteins (VLDL): ThenPrimary Lipid Abnormality in the Insulin Resistant StatenReasons for Elevated Free Fatty Acid Levels in Insulin Resistant StatesnFormation of Small, Dense LDL ParticlesnMechanisms Linking Insulin Resistance to Low HDL CholesterolnActivities of Lipoprotein and Hepatic Lipases and Their Relationshipsnto Atherogenic DyslipidemianLifestyle Management for Atherogenic DyslipidemianDrug Therapies for Atherogenic DyslipidemianIntensification of Efforts to Lower LDL-C as a Means of Achieving thenNon-HDL-C GoalnTargeting Triglyceride-rich Lipoprotein Reduction as a Means ofnAchievingNon-HDL-C GoalnManagement of Diabetic DyslipidemiannChapter 5nC-Reactive Protein and Other Inflammatory Markers in CardiovascularnDiseasenNatalie Khuseyinova, M.D.nWolfgang Koenig, M.D., Ph.D.nC-reactive ProteinnCytokinesnMarkers of Hemostasis, that are also Acute Phase ReactantsnPlasminogen Activator Inhibitor-1nD-DimernVon Willebrand FactornWhite Blood Cell Count nLipid-related BiomarkersnOxidised (Ox) LDLnLipoprotein-associated Phospholipase A2 (Lp-PLA2)nAdiponectinnnChapter 6nDietary Prescriptions to Control Dyslipidemias and Coronary Disease RisknMargo A. Denke, M.D.nA Diet-Enthusiast's Summary of The Evolving Role of DietnPre-Statin Cholesterol Lowering (1960-1987)nEarly Statin Years: LDL Lowering (1987-1994)nLandmark Statin Trials, LDL Lowering and Eruption of the MetabolicnSyndrome (1994-2004)nLipid Therapy Beyond LDL and CHD Prevention Dietary Therapies BeyondnLipids 2004-presentnnChapter 7nPharmacological Therapy for Cardiovascular Disease: Current andnEmerging TherapiesnMichael H. Davidson, M.D., F.A.C.C., F.A.C.P. nStatinsnEzetimibenBile Acid SequestrantsnNiacinnFibratesnOmega-3 Fatty Acids nnChapter 8nEffects of Thiazolidinediones on Serum LipoproteinsnAnjli Maroo, M.D., R.V.T.nW. H. Wilson Tang, M.D., F.A.C.C.nMechanisms of TZD Actions on Serum LipoproteinsnClinical Evidence of Lipid Lowering Effects of TZDsnMeta-Analyses of Pioglitazone and Rosiglitazone TrialsnProspective Comparative Clinical StudiesnConcomitant TZD and Statin TherapynOutcome StudiesnFuture DirectionsnnChapter 9nHigh-Density LipoproteinsnPeter P. Toth, M.D., Ph.D.nAntiatherogenic Effects of HDLnEpidemiologic Studies Evaluating the Relationship between HDL and Risknfor Cardiovascular DiseasenThe Definition and Prevalence of Low HDLnEffects of Lifestyle Modification on HDLnPharmacologic Therapy for Low
This book is an up-to-date and comprehensive reference on lipidology. It will serve as a stimulus to the reader to continue to learn about the ever changing and fascinating field of therapeutic lipidology. It will also empower readers to improve and extend the lives of the patients they so conscientiously serve.
An up-to-date, comprehensive reference on lipidology
Provides a focused and intensive source for the identification and management of dyslipidemias
Covers dyslipidemia management in obesity, cardiovascular disease, women, and children